FDA Cleared Opus Genetics’ IND Application For Opgx-RDH12, Investigational Gene Therapy For Treatment Of RDH12-Associated Leber Congenital Amaurosis

Opus Genetics, Inc. announced that the FDA has cleared its Investigational New Drug (IND) application for OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease. This clearance allows the company to proceed with clinical development of the therapy. The company is collaborating with the Global RDH12 Alliance, which includes patient advocacy organizations, to expedite the development of this treatment for patients with significant unmet medical needs.